News stories about Nevro Corp. (NYSE:NVRO) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Nevro Corp. earned a news sentiment score of 0.13 on Accern’s scale. Accern also assigned media coverage about the medical equipment provider an impact score of 44.7023916120052 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

A number of equities analysts recently commented on the company. BidaskClub downgraded shares of Nevro Corp. from a “sell” rating to a “strong sell” rating in a research report on Tuesday, November 14th. Northland Securities reiterated a “buy” rating and issued a $96.00 price target on shares of Nevro Corp. in a research report on Tuesday, November 7th. Canaccord Genuity dropped their price target on shares of Nevro Corp. from $120.00 to $110.00 and set a “buy” rating for the company in a research report on Tuesday, November 7th. Leerink Swann reiterated an “outperform” rating and issued a $110.00 price target (up from $105.00) on shares of Nevro Corp. in a research report on Tuesday, November 7th. Finally, Morgan Stanley lifted their price target on shares of Nevro Corp. from $87.00 to $95.00 and gave the company an “overweight” rating in a research report on Tuesday, August 8th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the stock. Nevro Corp. has an average rating of “Hold” and a consensus target price of $100.00.

Shares of Nevro Corp. (NYSE NVRO) traded down $2.45 during mid-day trading on Tuesday, hitting $76.83. 665,532 shares of the company were exchanged, compared to its average volume of 511,662. The company has a debt-to-equity ratio of 0.59, a quick ratio of 6.81 and a current ratio of 8.78. Nevro Corp. has a 12 month low of $65.82 and a 12 month high of $99.63.

Nevro Corp. (NYSE:NVRO) last released its earnings results on Monday, November 6th. The medical equipment provider reported ($0.21) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.02. The company had revenue of $82.26 million for the quarter, compared to analyst estimates of $80.50 million. Nevro Corp. had a negative net margin of 14.09% and a negative return on equity of 17.27%. The firm’s quarterly revenue was up 35.0% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.14) EPS. research analysts forecast that Nevro Corp. will post -1.27 EPS for the current year.

In related news, Director Wilfred E. Jaeger sold 52,520 shares of the business’s stock in a transaction dated Thursday, August 24th. The stock was sold at an average price of $86.11, for a total transaction of $4,522,497.20. Following the completion of the transaction, the director now owns 1,518 shares of the company’s stock, valued at approximately $130,714.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Michael F. Demane sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, October 5th. The shares were sold at an average price of $93.50, for a total value of $467,500.00. The disclosure for this sale can be found here. Insiders sold 115,987 shares of company stock worth $10,099,176 in the last three months. Insiders own 9.10% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at

About Nevro Corp.

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Insider Buying and Selling by Quarter for Nevro Corp. (NYSE:NVRO)

Receive News & Stock Ratings for Nevro Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp. and related stocks with our FREE daily email newsletter.